Showing results (1-10 of 389) with videos related to
Sort By:
Pageof 39
Multiple Sclerosis and Related Disorders|March 20, 2026
Beyond the 2024 McDonald criteria for defining and diagnosing multiple sclerosisGavin Giovannoni, Edward J Thompson, Gary Cutter, et al.Neurology|November 12, 2003
Biologic impact of interferon antibodies, and complexities in assessing their clinical significanceRichard A RudickCleveland Clinic Journal of Medicine|November 30, 2011
Multiple sclerosis, natalizumab, and PML: helping patients decideRichard A RudickAlzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's diseaseRichard A RudickJournal of Neuroimaging : Official Journal of the American Society of Neuroimaging|July 2, 2004
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosisRichard A RudickMultiple Sclerosis and Related Disorders|December 10, 2020
Effect size - one size doesn't fit allGary CutterMultiple Sclerosis and Related Disorders|November 13, 2019
EFFECT size or statistical significance, where to put your moneyGary CutterMultiple Sclerosis (Houndmills, Basingstoke, England)|March 6, 2003
Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosisDeborah M Miller, Richard A Rudick, Monika Baier, et al.Current Opinion in Neurology|April 2, 2011
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugsMegan Hyland, Richard A RudickExpert Review of Neurotherapeutics|April 28, 2005
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MSRichard A Rudick, Alfred SandrockPageof 39